bauplan | $7,500,000 | (Apr 17, 2025)
Finch(US) | Undisclosed Amount | (Apr 17, 2025)
Glycomine Inc. | $115,000,000 | (Apr 17, 2025)
Certified by Founder
Lodge
Rampart Bioscience
start up
United States
- Delhi, California
- 25/10/2023
- Series A
- $85,000,000
Rampart Bioscience is evolving a new class of medicines for patients with genetically driven diseases. We integrate capabilities from a variety of key scientific disciplines — including gene delivery, protein sciences and clinical translation — to leap beyond the limitations of current gene therapies.
Powered by our novel non-viral DNA delivery system, we are on a path to achieve higher standards for potency, durability, redosability and safety. Together, we are working to reshape the treatment landscape for people in dire need of better options.
- Industry Biotechnology Research
- Website https://rampartbio.com/
- LinkedIn https://www.linkedin.com/company/rampart-bioscience/about/
Atomic(US1) | $3,000,000 | (Apr 17, 2025)
Skin Analytics | $19,833,225 | (Apr 17, 2025)
PeopleForce | $5,400,000 | (Apr 17, 2025)
telli (YC F24) | $3,600,000 | (Apr 17, 2025)
Blue Onion | $10,000,000 | (Apr 17, 2025)
Inephany | $2,200,000 | (Apr 17, 2025)
Luma Financial Technologies | $63,000,000 | (Apr 17, 2025)
Scout AI | $15,000,000 | (Apr 17, 2025)
Tundr | $8,187,552 | (Apr 17, 2025)